ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Mutant Non-small Cell Lung Cancer|HER2-positive Metastatic Breast Cancer|HER2 Gene Mutation|HER2 Amplification
Interventions: DRUG: ELVN-002|DRUG: Fam-Trastuzumab Deruxtecan-Nxki|DRUG: Trastuzumab emtansine
Sponsor: Enliven Therapeutics